The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.
Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS ...
Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or ...
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
Read on to discover how time spent at home has shown to impact treatment decision-making in older adults with acute myeloid ...
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic ...
Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives ...
Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme ...
Senti Biosciences, Inc. SNTI announced positive initial data from a phase I study that evaluated its chimeric antigen ...
Aptose Biosciences (APTO) announced that the National Cancer Institute, NCI, part of the National Institutes of Health, and Aptose Biosciences ...
A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include ...